This study aims to obtain preliminary data for utility of alternate biomarkers for monitoring glucose control in diabetic women during pregnancy and/or predicting risk of adverse neonatal events in these women.
This study aims to obtain preliminary data for utility of alternate biomarkers for monitoring glucose control in diabetic women during pregnancy and/or predicting risk of adverse neonatal events in these women. Our population is unique compared to published studies and contains significant numbers of African American women and overweight or obese women. Two of these markers have been examined in several other populations of pregnant women and have shown utility for both outcomes. However, the recommended levels of these markers need to be determined in specific populations as ethnicity and BMI affect the values. Values obtained in recruited women will be compared with biobank samples from women who have no evidence or history of diabetes. Additionally, two other potentially promising markers will be examined (beta-hydroxybutyrate and triglycerides). Both these analytes change during pregnancy and beta-hydroxybutyrate has shown correlation with large for gestational status or macrosomia in some studies. A combination of markers may be a better predictor of adverse neonatal outcomes than a single marker.
Study Type
OBSERVATIONAL
Enrollment
47
Serum will be collected from patients at multiple times during pregnancy for later analysis.
Washington University in St Louis
St Louis, Missouri, United States
Glucose Control
various measures of glucose control will be reported and compared to other biomarkers measured by the study
Time frame: up to 60 weeks from enrollment
Adverse Neonatal Events
various adverse neonatal events will be reported and compared to other biomarkers measured by the study
Time frame: up to 60 weeks from enrollment
Glycated Albumin
Levels of % glycated albumin will be measured in the various cohorts to see if correlations exist with glucose control and adverse neonatal events
Time frame: up to 60 weeks from enrollment
Glycated Serum Protein (GSP)
Levels of glycated serum protein will be measured in the various cohorts to see if correlations exist with glucose control and adverse neonatal events
Time frame: up to 60 weeks from enrollment
Beta-hydroxybutyrate
Levels of beta-hydroxybutyrate will be measured in the various cohorts to see if correlations exist with glucose control and adverse neonatal events
Time frame: up to 60 weeks from enrollment
Triglycerides
Levels of triglycerides will be measured in the various cohorts to see if correlations exist with glucose control and adverse neonatal events
Time frame: up to 60 weeks from enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.